LONDON, October 2, 2018 /PRNewswire/ --
Antibody-Drug Conjugates, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments & ALPs, Biosimilar Antibodies
The global next-generation antibody therapies market reached $4bn in 2017 and is estimated to reach $17bn by 2023. In 2017, the antibody-drug conjugates segment held 45%
(Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 217-page report you will receive 141 charts- all unavailable elsewhere.
The 217-page report provides clear detailed insight into the next-generation antibody therapies market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Global Next-Generation Antibody Therapies Market from 2018-2028
Forecast of the Global Next-Generation Antibody Therapies market by Submarket: Antibody Fragments & ALPs Antibody-Drug Conjugates Biosimilar Antibodies Bispecific Antibodies Engineered Antibodies
Forecast of the Global Antibody Fragments & ALPs submarket by Product: Kalbitor Other Antibody Fragments
Forecast of the Global Antibody-Drug Conjugates submarket by Product: Adcetris Kadcyla Mylotarg Other ADCs
Forecast of the Global Biosimilar Antibodies submarket by Product: Infliximab Adalimumab Rituximab Bevacizumab Trastuzumab Other Biosimilar mAbs
Forecast of the Global Bispecific Antibodies submarket by Product: Blincyto Hemlibra Other Bispecific Antibodies
Forecast of the Global Engineered Antibodies submarket by Product: Gazyva/Gazyvaro Poteligeo Fasenra Other Engineered Antibodies
This report provides individual revenue forecasts to 2028 for these regional and national markets: North America: US, Canada, and Mexico Europe: Germany, France, United Kingdom, Italy, Spain, Russia, and rest of Europe Asia-Pacific: Japan, China, Australia, South Korea, India, and rest of Asia-Pacific LAMEA: Brazil, Saudi Arabia, Republic of South Africa, Turkey, and rest of LAMEA
Our study discusses the selected leading companies that are the major players in the next-generation antibody therapies market: Amgen, Inc. GlaxoSmithKline (GSK) Kirin Holdings (Kyowa Hakko Kirin Co., Ltd.) Merck KGaA Novartis AG Pfizer, Inc. Roche Sanofi Seattle Genetics, Inc. Shire plc
This report discusses SWOT & STEP analysis of the next-generation antibody therapies market as well as factors that drive and restrain this market. This report also discusses the opportunities that can be tapped in this market.
This report also discusses selected at that are in the pipeline.
Visiongain's study is intended for anyone requiring commercial analyses for the next-generation antibody therapies market. You find data, trends and predictions.
Buy our report today Global Next-Generation Antibody Therapies Market Forecast 2018-2028: Antibody-Drug Conjugates, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments & ALPs, Biosimilar Antibodies
To request a report overview of this report please contact Sara Peerun at firstname.lastname@example.org or refer to our website: https://www.visiongain.com/report/global-next-generation-antibody-therapies-market-forecast-2018-2028/
AbbVie AbGenomics Ablynx AdAlta ADC Therapeutics Adnexus Affimed Therapeutics Agensys Alcon Alexion Algeta ASA Allergan ALMAC Group Ambrx Amgen arGEN-X Astellas Pharma AstraZeneca Bayer Biogen Idec BioNet Ventures Biotest BioWa Boehringer Ingelheim Bristol-Myers Squibb Cancer Drugs Fund CARBOGEN AMCIS Cascadian Therapeutics, Inc. Catalent Pharma Solutions Celgene Celldex Therapeutics Cephalon Cilag GmbH International Clovis Oncology Coldstream Laboratories Concortis Biosystems Corixa Covagen Crescendo Biologics CSL Behring CVie Therapeutics CytomX Therapeutics Daiichi Sankyo Defiante Farmaceutica Delenex Therapeutics Domantis Dutalys Dyax Eddingpharm Eisai Eli Lilly Emergent BioSolutions Endo Pharmaceuticals ESBATech Esperance Pharmaceuticals ETH Zurich FDA Five Prime Therapeutics Formation Biologics Fresenius Biotech F-Star Fujifilm Genentech Genmab Gilead Sciences Glenmark Glycart Glycotope Goodwin Biotechnology GSK Health Canada Igenica Immune Design Immunocore ImmunoGen Immunomedics IONTAS Janssen Biotech Jazz Pharmaceuticals Kalobios Karolinska Institute Kyowa Hakko Kirin Kyowa Medex LINDIS Biotech Lonza MacroGenics MedImmune Merck Merrimack Pharmaceuticals Mersana Therapeutics Merus Micromet Millennium Pharmaceuticals Molecular Partners MorphoSys MultiCell Immunotherapeutics (MCIT) National Institute of Diabetes and Digestive and Kidney Diseases Neopharm Neovii Biotech Nerviano Medical Sciences NHS NICE NMS Group Nordic Nanovector ASA Novartis Novartis Institutes for BioMedical Research (NIBR) NovImmune Oxford BioTherapeutics Oxis Biotech Pfizer Pharmacyclics Pieris Piramal Enterprises Piramal Healthcare PolyTherics ProBioGen Progenics ProStrakan Redwood BioScience Roche Salix Sanofi Scil Proteins Seattle Genetics Servier Shinogi Shire Sigma-Tau Simcere Pharmaceutical Group Sorrento Therapeutics Spectrum Pharmaceuticals Spirogen Stelis Biopharma Stemcentrx Strides Arcolab Sutro Biopharma Swedish Orphan Biovitrum (Sobi) Swiss Federal Institute of Technology Synthon Synthon Biopharmaceuticals Takeda Talon Therapeutics Teva TG Therapeutics The American Society of Hematology The University of Texas MD Anderson Cancer Center TRION Pharma UCB WHO Wyeth Xencor Zydus Cadila Zymeworks
To see a report overview please e-mail Sara Peerun on email@example.com
Subscribe to our Free Newsletters!